

***Ximenia americana* heteropolysaccharides ameliorates inflammation and visceral hypernociception in murine caerulein-induced acute pancreatitis: involvement of CB2 receptors**

Kaira Emanuella Sales da Silva-Leite<sup>a,e</sup>, Deysen Kerlla Fernandes Bezerra Girão<sup>b</sup>, Alana de Freitas Pires<sup>a</sup>, Ana Maria S. Assreuy<sup>a</sup>, Pedro Almir Feitosa de Moraes<sup>b</sup>, Arcelina Pacheco Cunha<sup>c</sup>, Nágila Maria Pontes Silva Ricardo<sup>c</sup>, David Neil Criddle<sup>d</sup>, Marcellus Henrique Loiola Ponte de Souza<sup>e</sup>, Maria Gonçalves Pereira<sup>a,f</sup>, Pedro Marcos Gomes Soares<sup>b, e,\*</sup>

<sup>a</sup>Superior Institute of Biomedical Sciences, State University of Ceara, Av. Dr. Silas Munguba, 1700, Itaperi, 60714-903, Fortaleza, CE, Brazil

<sup>b</sup>Department of Morphology, Federal University of Ceara, Coronel Nunes de Melo Street, 1315 Rodolfo Teófilo, 60416-030, Fortaleza-CE, Brazil

<sup>c</sup> Department of Organic and Inorganic Chemistry, Federal University of Ceara, Humberto Monte Street, S/N, Campus de PICI, 60440554, Fortaleza, CE, Brazil

<sup>d</sup>Department of Cellular & Molecular Physiology, Institute of Translational Medicine, University of Liverpool, L69 3BX, Liverpool, United Kingdom

<sup>e</sup> Department of Physiology and Pharmacology, Laboratory of Physiopharmacology Study of Gastrointestinal Tract, Federal University of Ceará, Coronel Nunes de Melo Street, 1315 Rodolfo Teófilo, 60416-030, Fortaleza-CE, Brazil

<sup>f</sup> Faculty of Education Science and Letters of the Hinterland, José de Queiroz Pessoa Street, 2554 – Planalto Universitário, 63.900-000, Quixadá, CE, Brazil

*Abbreviations:* TPL-Xa, Total polysaccharide of *X. americana*; AP, acute pancreatitis; MPO, myeloperoxidase; CGRP, Calcitonin Gene-Related Peptide; SP, substance P; TRPV1, Transient Receptor Potential Vanilloid 1; CB1, cannabinoid receptor type 1; CB2, cannabinoid receptor type 2; NF- $\kappa$ B, Nuclear factor- $\kappa$ B; NMR, nuclear magnetic resonance.

*\*Corresponding author:* Coronel Nunes de Melo Street, 1315 Rodolfo Teófilo, CEP: 60.430-270, Fortaleza, Ceará, Brazil; \*E-mail addresses: pedrogsoares@yahoo.com.br.

*E-mail addresses authors:* kairaemanuella@hotmail.com (K.E.S. Silva-Leite), deysen\_cmdm@hotmail.com (D.K.F.B. Girão), alanapires@hotmail.com (A.F. Pires), ana.assreuy@uece.br (A.M.S. Assreuy), pedroalmir12@hotmail.com (P.A.F. de

Moraes) arcelinapacheco@yahoo.com.br (A.P. Cunha), naricard@ufc.br (N.M.P.S. Ricardo), criddle@liv.ac.uk (D.N. Criddle), souzamar@ufc.br (M.H.L. Ponte), maria.pereira@uece.br (M.G. Pereira).

## **Abstract**

*Background:* This study aimed to characterize and investigate the anti-inflammatory and anti-hypernociceptive effects of the total polysaccharide of *X. americana* (TPL-Xa) bark and the of cannabinoid receptors in a mouse model of acute pancreatitis-induced by caerulein

*Methods:* TPL-Xa was characterized by <sup>1</sup>H and <sup>13</sup>C RMN spectroscopy. Animals received TPL-Xa (10 mg/kg, i.v.) 30 min before and after caerulein (50 µg/kg, 10x, i.p.) administration. To evaluate the involvement of cannabinoid receptors, AM281 (3 mg/kg, s.c.) and AM630 (1 mg/kg, s.c.) were administered 30 min before TPL-Xa. Plasma levels of amylase and lipase, pancreatic myeloperoxidase (MPO), histology, visceral hypernociception and motor coordination were evaluated 11 and 24 h after acute pancreatitis (AP). *Results:* TPL-Xa, containing a heteropolysaccharide composed of glucose, galactose, arabinose, rhamnose, fucose and galacturonic acid, reduced amylase and lipase levels, MPO activity, acinar cell necrosis, edema and neutrophil infiltration. TPL-Xa increased the threshold of visceral hypernociception, that was reversed by AM630, an antagonist of cannabinoid receptors type 2 (CB2). In addition, TPL-Xa did not alter the animals motor coordination.

*Conclusions:* TPL-Xa contains heteropolysaccharides that inhibits the inflammation and hypernociception in the experimental model of caerulein-induced AP, by a mechanism involving type CB2 receptors.

*Keywords:* pancreas inflammatory nociception; medicinal plant polysaccharides; structural characterization; cannabinoid receptors.

## **1. Introduction**

Acute pancreatitis is an inflammatory pancreas disorder, mainly caused by the presence of gallstones and alcohol abuse [1,2]. Its incidence varies from 5 to 80 per 100.000 individuals per year [3] and is manifested by elevated serum levels of pancreatic enzymes and acute pain [4,5]. The pain management is still a major challenge, since there are patients refractory to the current therapies, a lack of

investigation of visceral pain pathophysiology [6] and side effects of the standard treatment with opiates [7].

The cannabinoid system has emerged as an important antinociceptive pathway, since the cannabinoid receptors are distributed in anatomical regions (medulla dorsal horn, periaqueductal gray matter) involved in pain transmission and modulation [8]. It has been demonstrated that the activation of cannabinoid receptors (CB1, CB2) reduces hypernociception in a model of irritable bowel syndrome [9], and in models of acute [10–12] and chronic pancreatitis [13]. These protective effects were also observed *in vitro* models of pancreatic acinar cell injury [14,15]. Consequently, substances that interfere with other nociceptive pathways, such as the cannabinoid system, have been considered as alternatives for pain modulation [16].

Plant polysaccharides are molecules known for their modulatory effects on the immune system [17], such as inflammation [18,19] and nociception. The antinociceptive effects were demonstrated in the mice visceral nociception induced by acetic acid for the polysaccharides of *Thladiantha dubia* [20], *Solanum betaceum* [21,22], *Solanum lycopersicum* [23]. In addition, polysaccharide rich fractions isolated from *Ximenia americana* barks, a plant popularly used as anti-inflammatory and analgesic [24,25,26]. Also, in the model of caerulein-induced experimental acute pancreatitis the polysaccharide of lemon (low-methoxyl pectin) attenuated the inflammatory response and improved intestinal barrier integrity [27]. The total polysaccharides fraction (TPL-Xa: 8.1% yield) presented 43% carbohydrate (21% uronic acid) and resulted in two main fractions after chromatography (FI: 12%, FII: 22% yield). FII showed better homogeneity/purity, content of 44% carbohydrate, including 39% uronic acid, arabinose and galactose as major monosaccharides, and infrared spectra with peaks in carbohydrate range for COO–groups of uronic acid [24].

This study aimed to analyze the structural features of total polysaccharides of *X. americana* barks and to evaluate their anti-inflammatory and antinociceptive effects in the model of acute pancreatitis induced by caerulein in mice. The involvement of cannabinoid receptors in their beneficial effects was also evaluated.

## **2. Materials and Methods**

### *2.1. Chemicals*

Caerulein and the reagents for dosage of MPO (myeloperoxidase) were obtained from Sigma Aldrich (St. Louis, MO-USA); ketamine and 2% xylazine König S/A (Hurlingham, Buenos Aires, Argentina); antagonists of cannabinoid receptors CB1 (AM281) and CB2 (AM630) from Tocris Bioscience (Ellisville, MD, EUA); commercial kits for amylase from Labtest (Lagoa Santa, MG, Brazil) and lipase from Bioclin (Belo Horizonte, MG, Brazil) and diazepam from TEUTO S/A (Anápolis, GO, Brazil). The remaining drugs and reagents were of analytical grade.

## 2.2. Polysaccharides extraction and structural characterization

Bark of *X. americana* L (voucher n° 46794/Herbarium Prisco Bezerra - Federal University of Ceará), collected at Custódio- Quixadá, Ceará, Brazil, were washed, dried at 40 °C and macerated into powder. Five grams of dry powder were suspended in absolute methanol for depigmentation, extraction with 0.1 M NaOH and precipitation in ethanol, resulting in the total polysaccharides (TPL-Xa: 8.1% yield, containing 43% total carbohydrates, including 21% uronic acid and 6.5% proteins) [24].

<sup>1</sup>H and <sup>13</sup>C Nuclear Magnetic Resonance (NMR) of TPL-Xa was performed in the Fourier transform Bruker Avance DRX 500 spectrometer (USA, California), equipped by reverse detection probe, operating at 499.9 MHz (<sup>1</sup>H) or 125 MHz (<sup>13</sup>C), in the window spectral ratio of 20 ppm for <sup>1</sup>H or 200 ppm for <sup>13</sup>C. TPL-Xa (32 mg) was solubilized in D<sub>2</sub>O (3% m/v). The analysis was carried out at 24 °C and residual water signal at 4.79 and chemical shifts (δ) expressed in ppm.

## 2.3. Animals

Male Swiss mice (20-25 g) were housed in a climate-controlled room and maintained at 22-26 °C in a 12 h light/12 h dark cycle, fed with standard chow, water *ad libitum* and allowed to acclimatize for a minimum of 1 week. The experimental protocols were approved by the Institutional Animal Care and Use Committee of the State University of Ceará (n° 3202316/2014; 06/2014).

## 2.4. Acute pancreatitis model and treatment with TPL-Xa

Acute pancreatitis was induced by ten injections of caerulein (50 µg/kg), administered by intraperitoneal (i.p.) route at hourly intervals [12]. The control animals received saline i.p. Animals were treated with TPL-Xa (10 mg/kg or saline by intravenous (i.v.) route 30 min before the first, and 30 min after the last injection of caerulein. To evaluate the involvement of cannabinoid receptors in the TPL-Xa effects, AM281 (CB1-specific antagonist, 3 mg/kg and AM630 (CB2-specific antagonist, 1 mg/kg) were administered by subcutaneous (s.c.) route in non-treated or treated animals 30 min before TPL-Xa. After the 11<sup>th</sup> and 24<sup>th</sup> hours following the first injection of caerulein, mice were anesthetized (ketamine and 2% xylazine) for collection of blood samples and sacrifice. The pancreas was rapidly removed and frozen at -80 °C for evaluation of myeloperoxidase activity, or fixed in formalin (10%) for histopathological analysis.

### *2.5. Serum amylase and lipase*

Blood samples were taken and centrifuged at 3500 rpm for 10 min. The serum amylase and lipase levels were measured by colorimetric method using commercial kits. The values of amylase and lipase were expressed as units of enzyme U/dL and U/L, respectively.

### *2.6. Pancreatic myeloperoxidase activity*

Samples of pancreatic tissue were homogenized in 0.5% hexa-decyl-trimethyl-ammonium bromide (50 mg of tissue/500 µl) and centrifuged (40000 × g, 20 min, 4 °C). Supernatants were incubated in 96-well plates (10 µL) with a mixture of 5 mg O-dianisidine, 15 µL 1% H<sub>2</sub>O<sub>2</sub>, 3 mL phosphate buffer and 27 mL H<sub>2</sub>O and measured at 450 nm for 1 min in microplate reader (BMG FLUOstar OPTIMA) [28]. One unit of MPO activity was defined as that degrading 1 mmol of peroxide per min at 25 °C and expressed as U/mg of tissue.

### *2.7. Histopathological analysis*

Mice were euthanized at 11 and 24 h after pancreatitis induction. The pancreas was excised, fixed with 10% buffered formalin for 24 h, embedded in paraffin, cut into

5 µm thick sections and stained with hematoxylin-eosin (HE). The assessment of pancreatic edema, inflammatory cell infiltrate and acinar necrosis were graded with scores ranging from 0 to 3 [29] under light microscopy.

#### *2.8. Mechanical visceral hypernociception (von Frey test)*

Mice were placed in clear acrylic box with raised platforms of wire mesh, 15 min before the test. The abdominal hypernociceptive reaction (licking of the abdomen, abdominal and/or whole-body withdrawal) was evoked by application of a gradual pressure (g) using polypropylene tip (0.5 mm<sup>2</sup> contact area) coupled to a hand-held force transducer (Electronic von Frey Aesthesiometer; Insight). Hypernociception was evaluated at baseline (time zero - mean of three measurements) and 11 and 24 h after the first dose of caerulein [30].

#### *2.9. Rota-rod test*

After 30 min of TPL-Xa treatment, the animals locomotor function was assessed. Diazepam (5 mg/kg, i.p.) was used as a positive control. Mice had been selected 24 h prior to the test, excluding those that did not remain on the Rota-rod (22 r.p.m.) for at least two consecutive periods of 60 s. The time in which animals remained on the apparatus was recorded [31].

#### *2.10. Western blot analysis*

The Pancreatic tissue was macerated in lysis buffer, after centrifugation, the proteins were dosed by the BCA method (Sigma-Aldrich). For immunoblotting, the samples were subjected to 10% SDS-PAGE and homogeneous transfer to nitrocellulose membranes. Membranes were blocked with TBS-T buffer and 5% milk for 1 h at room temperature. For protein detection, blotted membrane was incubated with the specific anti-CB2 (1:200; SC) overnight at 4-8° C. Membranes were incubated for one hour at room temperature with conjugated secondary antibodies (anti-rabbit, 1:2500; Santa Cruz). The blots will be revealed using hemiluminescence technique (ECL plus system).

### 2.11. Statistical analysis

Parametric results are presented as mean  $\pm$  S.E.M and analysed by One-way analysis of variance (ANOVA) followed by the Bonferroni t-test. Histological analyses were presented as median (maximum and minimum) and analysed by Kruskal-Wallis followed by a Dunn test. Values of  $p < 0.05$  were considered significant.

## 3. Results

### 3.1. $^1\text{H}$ and $^{13}\text{C}$ NMR spectra of TPL-Xa

The  $^1\text{H}$  NMR spectra of TPL-Xa revealed a large signal of chemical displacement ( $\delta$ ) in 3.83 ppm, attributed to the group -O-CH<sub>3</sub>, and a minor signal at 1.17 ppm, suggestive of a methyl group linked to L-fucose monomer [32]. Other signals were also revealed: at 1.25 and 1.31 ppm corresponding to methyl groups of L-rhamnose unit; at 1.91 ppm indicated the presence of galacturonic acid acetyl groups [33] and at 5.40 and 5.25 ppm, corresponding, respectively, to H1 of unsubstituted/substituted  $\alpha$ -L-arabinose. Besides, signals between 5.09-5.19 ppm are possibly related to H1  $\alpha$ -D-glucose and  $\alpha$ -D-galactose [32,34,35], and 3.0-4.5 ppm are attributed to the hydrogens (H2-H6) of  $\alpha$ -D-glucose,  $\alpha$ -D-galactose or  $\alpha$ -L-arabinose [32]. In the  $^{13}\text{C}$  NMR spectra, signals at 107.47 and 106.89 ppm possibly correspond to anomeric carbons of unsubstituted/substituted  $\alpha$ -L-arabinose, respectively, and those at 99.66 and 95.72 ppm correspond to C1 of the pyranoside ring of  $\alpha$ -D-glucose and  $\alpha$ -D-galactose, respectively [32,36]. The signal at 57.38 ppm could be attributed to -O-CH<sub>3</sub> bound to galacturonic acid carboxylate [34]. Signals between 55.0-85.0 ppm could be carbon chains (C2-C6) of  $\alpha$ -D-glucose,  $\alpha$ -D-galactose and  $\alpha$ -L-arabinose [35,36], and at 16.44 ppm attributed to L-fucose.

### 3.2. Inhibitory effect of TPL-Xa on pancreatic enzymes and inflammatory parameters

Caerulein induced acute pancreatitis was characterized by a significant increase in the levels of serum amylase and lipase at the 11<sup>th</sup> and the 24<sup>th</sup> hour after the first caerulein injection compared to saline. TPL-Xa reduced the elevated levels of amylase at the 11<sup>th</sup> h by 28.5% (Fig. 2A) and at the 24<sup>th</sup> h by 26.6%, while lipase levels were

reduced only at the 11<sup>th</sup> h by 52% (Fig. 2B). Caerulein also caused pancreatic tissue damage (edema, inflammatory infiltration and acinar cell necrosis) (Fig. 3 A-D) and increased MPO activity (Fig. 4). Administration of TPL-Xa markedly reduced the histological parameters at the 11<sup>th</sup> h: edema, inflammatory infiltration, acinar cell necrosis and total scores. TPL-Xa reduced the MPO activity by 56% at the 11<sup>th</sup> h (Fig. 4A), but caused no alteration at 24<sup>th</sup> h (Fig. 4B).

### *3.3. TPL-Xa inhibits visceral hypernociception without alteration of locomotor function*

The acute pancreatitis induced by repeated doses of caerulein reduced the threshold of nociceptive responses at the 11<sup>th</sup> h and 24<sup>th</sup> h. TPL-Xa increased the threshold of visceral hypernociception by 42% only at the 11<sup>th</sup> h after first caerulein injection (Fig. 5A). TPL-Xa did not alter the latency of animal permanence in the Rota-rod. The sedative agent diazepam decreased this latency (Fig. 5B).

### *3.4. Involvement of CB2 cannabinoid receptors in the anti-hypernociceptive effect of TPL-Xa.*

The threshold of hypernociception in animals with acute pancreatitis was not altered by the administration of selective CB1/CB2 antagonists (Fig. 6B;D). However, the administration of AM630 (selective antagonist of CB2 receptors), but not of AM281 (selective antagonist of CB1 receptors) reversed the TPL-Xa protective effect (Fig. 6 B;D). In addition, AM 630 reversed the protection of TPL-Xa observed in total histopathological scores (Fig. 6E) and the inhibition of CB2 receptor expression (Fig. 6F).

Before treatments (time zero of the von Frey test) no differences were observed between groups (Fig. 6A;C).

## **4. Discussion**

In this study a heteropolysaccharide was identified in the polysaccharide extract obtained from the medicinal plant *X. americana* barks (TPL-Xa). This heteropolysaccharide was shown to be composed of  $\alpha$ -D-glucose,  $\alpha$ -D-galactose,  $\alpha$ -L-



arabinose,  $\alpha$ -rhamnose, L-fucose and galacturonic acid, and reduced the inflammatory parameters of caerulein-induced acute pancreatitis in mice.

The  $^1\text{H}$  and  $^{13}\text{C}$  NMR spectra of TPL-Xa corroborates other data demonstrated by chemical analysis, agarose gel electrophoresis, monosaccharide composition and infrared spectra previously showed for the two major polysaccharide rich fractions isolated from TPL-Xa. This fractions revealed the presence of uronic acid (8-39%), arabinose (39-57%), rhamnose (4-7%), galactose (16-20%) and glucose (7-35%) in its monosaccharide composition and infrared spectra demonstrated peaks in carbohydrate range for  $\text{COO}^-$  groups of uronic acid [24]. Importantly, some studies have related the presence of these acidic compounds of the cell wall of plants with some biological activities, such as, antitussive, antioxidant, anti-inflammatory and anticoagulant [37,38,39]. Thus, it is possible to speculate that the presence of uronic acid residues (21%) in the *X. americana* heteropolysaccharide may be contributing to the inhibitory effect of TPL-Xa on inflammatory parameters of acute pancreatitis induced by cerulein. However, additional trials to assess the relationship structure-activity are still required. Furthermore, in other studies, phytochemical screening for major constituents for ethanol and water extracts of *Ximenia americana* barks demonstrated also the presence of saponins, tannins, flavonoids, alkaloids, phenolics, glycosides, resins, quinones and terpenoids [40,41].

TPL-Xa protected the inflammatory damage seen by the decrease of histological alterations (edema, neutrophil infiltration and acinar necrosis) and MPO activity, a common indirect marker of neutrophil infiltration [28] and oxidative stress [42]. The model of hyperstimulation of murine exocrine pancreas with caerulein, a cholecystokinin analogue, is one of the most widely used and the best characterized model of acute pancreatitis due to its high applicability, rapid induction, reproducibility and low invasiveness [43]. Hyperstimulation of isolated mouse pancreatic acinar cells with cholecystokinin causes sustained cytosolic calcium overload and intracellular trypsin activation resulting in cell death [44]. One of the consequences of pancreatic enzymatic activation is a local inflammatory response, characterized by oedema and neutrophil infiltration, the latter closely associated to the development of caerulein-induced acute pancreatitis [45].

Our data suggest that the protective action of TPL-Xa in pancreatic inflammation may particularly involve reduction of neutrophil infiltration, an effect already demonstrated for plant polysaccharides [18,19,46,47]. In addition, previous data

has demonstrated in mice that the ethanolic extract of *X. americana* bark reduced cell migration in carrageenan-induced peritonitis in mice [48]. These data all together support the anti-inflammatory use of *X. americana* bark in folk medicine [25].

In the present study, we also demonstrated that TPL-Xa attenuated the visceral hypernociception in caerulein-induced AP via mechanisms that involve cannabinoid receptors, since the pretreatment with CB2 receptor antagonist (AM630) partially reversed the antinociceptive effect of TPL-Xa.

The cannabinoid system modulates acute and chronic pain from several diseases [49,50]. Previous studies suggested the involvement of endocannabinoids in acute pancreatitis [12,51]; HU210, a potent central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptor agonist, inhibited inflammation and pancreatic hypernociception in the caerulein-induced model of AP in mice [12]. Therefore mice lacking of CB1 in primary nociceptors developed higher hypernociception to abdominal mechanical stimuli after pancreatic inflammation [51]. The CB2 receptor subtype has a widespread distribution in the immune system [52], including endocrine and pancreas exocrine cells [53] and CB2 receptor agonists have significant antinociceptive actions in neuropathic [54] chronic [55] and inflammatory [56] pain models. Additionally, activation of CB2 receptors may exert anti-inflammatory effects via reduction of NF- $\kappa$ B [57]. However, no specific data are available in exocrine pancreas. In fact, the role of the cannabinoid system in the development of AP and the relevance of endocannabinoid receptor subtype involvement remains unclear [58]. Consistent with the previous study, we found an increase in CB2 expression in pancreatic tissue with caerulein-induced AP [12]. In our evaluation, the effect was decreased by the treatment with TPL-X and the effect was lost after the treatment with the CB2 receptor antagonist, justifying the effect found in the Frey test.

Despite the importance of pain in pancreatitis, its pathophysiological mechanisms are still poorly understood. However, it is recognised that this type of pain is characterized as being recurrent, hyperalgesia intense and long-lasting [59] and is associated with decrease in the threshold to mechanical stimulation of the abdominal region, an area of referred pain [30]. In the present study, TPL-Xa attenuated visceral hypernociception induced by pancreatitis in mice, increasing the threshold to mechanical stimuli (von Frey test). This action of TPL-Xa on inflammatory pain and hypernociception in acute pancreatitis is consistent with the wellknown activities of plant polysaccharides in the immune system [60,61], including anti-inflammatory

[18,19,62]. Studies in mice have recently demonstrated antinociceptive activities in visceral inflammatory pain of crude polysaccharide extracts of *Thladiantha dubia* Bunge [20] and polysaccharides isolated from *Solanum betaceum* Cav. fruit (tamarillo) and *Solanum lycopersicum* L [21–23]. Furthermore, the inhibitory effect of the aqueous extract and polysaccharide fractions of *X. americana* barks has been previously demonstrated in classic models of nociception, including in the visceral nociception induced by acetic acid [24,63]. Furthermore, this data is consistent with the popular use of *X. americana* in painful conditions, such as stomachache and headache [25,64].

It is important to highlight, that the systemic treatment of animals with TPL-Xa did not alter locomotor activity, a common adverse side effect of analgesic drugs. Therefore, polysaccharides obtained from natural sources represent a structurally diverse class of macromolecules known to modulate a variety of biological responses, causing low toxicity [17].

In conclusion, the total polysaccharides obtained from *X. americana* bark contain a heteropolysaccharide that possesses anti-inflammatory and antinociceptive effects in caerulein experimental acute pancreatitis, actions involving cannabinoid type 2 receptors.

### **Conflict of interest**

The authors declare no competing financial interest.

### **Acknowledgements**

This research was supported by CAPES and FUNCAP (Research Program for SUS - PPSUS, nº 12535684-6:03/2012).

### **References**

G.S. Oh, H.J. Kim, A. Shen, S.B. Lee, D. Khadka, A. Pandit, Cisplatin-induced kidney dysfunction and perspectives on improving treatment strategies, *Electrolytes Blood Press.* 12 (2014) 55–65.

- [1] G.-J. Wang, C.-F. Gao, D. Wei, C. Wang, S.-Q. Ding, Acute pancreatitis: etiology and common pathogenesis, *World. J. Gastroenterol.* 15 (2009) 1427–1430.
- [2] D.N. Criddle, The role of fat and alcohol in acute pancreatitis: a dangerous

- liaison, *Pancreatology*. 15 (2015) 6–12.
- [3] J.E. Abela, C.R. Carter, Acute pancreatitis – a review, *Surg.* 28 (2010) 205–211.
- [4] M. V Singer, K. Gyr, H. Sarles, Revised classification of pancreatitis. Report of the Second International Symposium on the Classification of Pancreatitis in Marseille, France, March 28-30, 1984., *Gastroenterology*. 89 (1985) 683–685.
- [5] E.S. Schwartz, J.A. Christianson, X. Chen, J.-H. La, B.M. Davis, K.M. Albers, et al., Synergistic role of TRPV1 and TRPA1 in pancreatic pain and inflammation, *Gastroenterology*. 140 (2011) 1283-1291.
- [6] P. Bhardwaj, P.K. Garg, S.K. Maulik, A. Saraya, R.K. Tandon, S.K. Acharya, A randomized controlled trial of antioxidant supplementation for pain relief in patients with chronic pancreatitis, *Gastroenterology*. 136 (2009) 149–159.
- [7] E.C. Wick, S. Pikiros, E.F. Grady, K.S. Kirkwood, Calcitonin gene-related peptide partially mediates nociception in acute experimental pancreatitis, *Surgery*. 139 (2006) 197–201.
- [8] M. Herkenham, A.B. Lynn, M.D. Little, M.R. Johnson, L.S. Melvin, B.R. de Costa, et al., Cannabinoid receptor localization in brain, *Proc. Natl. Acad. Sci. U. S. A.* 87 (1990) 1932–1936.
- [9] A. Kikuchi, K. Ohashi, Y. Sugie, H. Sugimoto, H. Omura, Pharmacological evaluation of a novel cannabinoid 2 (CB2) ligand, PF-03550096, in vitro and in vivo by using a rat model of visceral hypersensitivity, *J. Pharmacol. Sci.* 106 (2008) 219–224.
- [10] T. Michler, M. Storr, J. Kramer, S. Ochs, A. Malo, S. Reu, et al., Activation of cannabinoid receptor 2 reduces inflammation in acute experimental pancreatitis via intra-acinar activation of p38 and MK2-dependent mechanisms, *Am. J. Physiol. Gastrointest. Liver Physiol.* 304 (2013) 181-192.
- [11] C. Petrella, S. Agostini, G.S. Alema', P. Casolini, F. Carpino, C. Giuli, et al., Cannabinoid agonist WIN55,212 in vitro inhibits interleukin-6 (IL-6) and monocyte chemo-attractant protein-1 (MCP-1) release by rat pancreatic acini and in vivo induces dual effects on the course of acute pancreatitis, *Neurogastroenterol. Motil.* 22 (2010) 1248-1257.
- [12] C.W. Michalski, T. Laukert, D. Sauliunaite, P. Pacher, F. Bergmann, N. Agarwal, et al., Cannabinoids ameliorate pain and reduce disease pathology in cerulein-induced acute pancreatitis, *Gastroenterology*. 132 (2007) 1968–1978.
- [13] L. Zhang, R.H. Kline, T.A. McNearney, M.P. Johnson, K.N. Westlund,

- Cannabinoid Receptor 2 Agonist Attenuates Pain Related Behavior in Rats with Chronic Alcohol/High Fat Diet Induced Pancreatitis, *Mol. Pain.* 10 (2014) 1-16.
- [14] Z. Huang, H. Wang, J. Wang, M. Zhao, N. Sun, F. Sun, et al., Cannabinoid receptor subtype 2 (CB2R) agonist, GW405833 reduces agonist-induced Ca(2+) oscillations in mouse pancreatic acinar cells, *Sci. Rep.* 6 (2016) 1-14.
- [15] C.W. Michalski, M. Maier, M. Erkan, D. Sauliunaite, F. Bergmann, P. Pacher, et al., Cannabinoids reduce markers of inflammation and fibrosis in pancreatic stellate cells, *PLoS One.* 3 (2008) 1-12.
- [16] J. Manzanares, M. Julian, A. Carrascosa, Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes, *Curr. Neuropharmacol.* 4 (2006) 239–257.
- [17] I.A. Schepetkin, M.T. Quinn, Botanical polysaccharides: macrophage immunomodulation and therapeutic potential., *Int. Immunopharmacol.* 6 (2006) 317–333.
- [18] L. de P. Pereira, K.E.S. da Silva, R.O. da Silva, A.M.S. Assreuy, M.G. Pereira, Anti-inflammatory polysaccharides of *Azadirachta indica* seed tegument, *Rev. Bras. Farmacogn.* 22 (2012) 617–622.
- [19] L. de P. Pereira, R.O. da Silva, P.H. de S.F. Bringel, K.E.S. da Silva, A.M.S. Assreuy, M.G. Pereira, Polysaccharide fractions of *Caesalpinia ferrea* pods: potential anti-inflammatory usage, *J. Ethnopharmacol.* 139 (2012) 642–648.
- [20] L. Wang, D. Zhao, L. Di, T. Xu, X. Lin, B. Yang, et al., The analgesic and anti-rheumatic effects of *Thladiantha dubia* fruit crude polysaccharide fraction in mice and rats, *J. Ethnopharmacol.* 137 (2011) 1381–1387.
- [21] G.E. do Nascimento, L.A. Hamm, C.H. Baggio, M.F. de P. Werner, M. Iacomini, L.M.C. Cordeiro, Structure of a galactoarabinoglucuronoxylan from tamarillo (*Solanum betaceum*), a tropical exotic fruit, and its biological activity., *Food Chem.* 141 (2013) 510–516.
- [22] G.E. do Nascimento, C.R. Corso, M.F. de Paula Werner, C.H. Baggio, M. Iacomini, L.M.C. Cordeiro, Structure of an arabinogalactan from the edible tropical fruit tamarillo (*Solanum betaceum*) and its antinociceptive activity, *Carbohydr. Polym.* 116 (2015) 300–306.
- [23] G.E. Do Nascimento, C.H. Baggio, M.F. De, P. Werner, M. Iacomini, L.M.C. Cordeiro, Arabinoxylan from Mucilage of Tomatoes (*Solanum lycopersicum* L.): Structure and Antinociceptive Effect in Mouse Models, *J. Agric. Food Chem.* 64

(2016) 1239–1244.


- [24] K.E.S. da Silva-Leite, A.M.S. Assreuy, L.F. Mendonça, L.E.A. Damasceno, M.G.R. de Queiroz, P.A.S. Mourão, et al., Polysaccharide rich fractions from barks of *Ximenia americana* inhibit peripheral inflammatory nociception in mice, *Rev. Bras. Farmacogn.* 27 (2017) 339–345.
- [25] U.P. de Albuquerque, P. Muniz de Medeiros, A.L.S. de Almeida, J.M. Monteiro, E. Machado de Freitas Lins Neto, J. Gomes de Melo, et al., Medicinal plants of the caatinga (semi-arid) vegetation of NE Brazil: a quantitative approach., *J. Ethnopharmacol.* 114 (2007) 325–354.
- [26] R.K.D. Souza, M.A.P. da Silva, I.R.A. de Menezes, D.A. Ribeiro, L.R. Bezerra, M.M. de A. Souza, Ethnopharmacology of medicinal plants of carrasco, northeastern Brazil, *J. Ethnopharmacol.* 157 (2014) 99–104.
- [27] Y. Sun, Y. He, F. Wang, H. Zhang, P. de Vos, J. Sun, Low-methoxyl lemon pectin attenuates inflammatory responses and improves intestinal barrier integrity in caerulein-induced experimental acute pancreatitis, *Mol. Nutr. Food Res.* 61 (2017) 1-9.
- [28] P.P. Bradley, R.D. Christensen, G. Rothstein, Cellular and extracellular myeloperoxidase in pyogenic inflammation, *Blood.* 60 (1982) 618–622.
- [29] S. Wildi, J. Kleeff, J. Mayerle, A. Zimmermann, E.P. Böttinger, L. Wakefield, et al., Suppression of transforming growth factor beta signalling aborts caerulein induced pancreatitis and eliminates restricted stimulation at high caerulein concentrations, *Gut.* 56 (2007) 685–692.
- [30] J.M. Laird, L. Martinez-Caro, E. Garcia-Nicas, F. Cervero, A new model of visceral pain and referred hyperalgesia in the mouse, *Pain.* 92 (2001) 335–342.
- [31] F.E. D'amour, D.L. Smith, A method for determining loss of pain sensation, *J. Pharmacol. Exp. Ther.* 72 (1941) 74–79.
- [32] F.F. Simas-Tosin, R.R. Barraza, D. Maria-Ferreira, M.F. de P. Werner, C.H. Baggio, R. Wagner, et al., Glucuronoarabinoxylan from coconut palm gum exudate: Chemical structure and gastroprotective effect, *Carbohydr. Polym.* 107 (2014) 65–71.
- [33] K. Alba, A.P. Laws, V. Kontogiorgos, Isolation and characterization of acetylated LM-pectins extracted from okra pods, *Food Hydrocoll.* 43 (2015) 726–735.
- [34] D. Das, S. Mondal, S.K. Roy, D. Maiti, B. Bhunia, T.K. Maiti, et al., Isolation

- and characterization of a heteropolysaccharide from the corm of *Amorphophallus campanulatus*, Carbohydr. Res. 344 (2009) 2581–2585.
- [35] L. Ye, J. Zhang, Y. Yang, S. Zhou, Y. Liu, Q. Tang, et al., Structural characterisation of a heteropolysaccharide by NMR spectra, Food Chem. 112 (2009) 962–966.
- [36] Y. Huang, N. Li, J.-B. Wan, D. Zhang, C. Yan, Structural characterization and antioxidant activity of a novel heteropolysaccharide from the submerged fermentation mycelia of *Ganoderma capense*, Carbohydr. Polym. 134 (2015) 752–760.
- [37] G. Nosál'ová, A. Kardosová, S. Franová, Antitussive activity of a glucuronoxylan from *Rudbeckia fulgida* compared to the potency of two polysaccharide complexes from the same herb, Pharmazie. 55 (2000), 65-68.
- [38] S.J. Yoon, M.S. Pereira, M.S.G. Pavão, J.K. Hwang, Y.R. Pyun, P.A.S. Mourão, The medicinal plant *Porana volubilis* contains polysaccharides with anticoagulant activity mediated by heparin cofactor II. Thromb. Res. 106 (2002) 51-58.
- [39] H. Chen, M. Zhang, B. Xie, Quantification of uronic acids in tea polysaccharide conjugates and their antioxidant properties. J. Agric. Food Chem. 52 (2004) 3333-3336.
- [40] M.H. Shagal, D. Kubmarawa, J.T. Barminas, Evaluation of antimicrobial property of *Ximenia americana*, E3 J. Biotechnol. Pharm. Res. 4 (2013) 99–102.
- [41] V.A. Maikai, B.V. Maikai, P.I. Kobo, Antimicrobial Properties of Stem Bark Extracts of *Ximenia americana*, J. Agric. Sci. 1 (2009) 30.
- [42] M.B. Hampton, A.J. Kettle, C.C. Winterbourn, Inside the neutrophil phagosome: oxidants, myeloperoxidase, and bacterial killing., Blood. 92 (1998) 3007–3017.
- [43] M.M. Lerch, F.S. Gorelick, Models of Acute and Chronic Pancreatitis, Gastroenterology. 144 (2013) 1180–1193.
- [44] D.N. Criddle, D.M. Booth, R. Mukherjee, E. McLaughlin, G.M. Green, R. Sutton, et al., Cholecystokinin-58 and cholecystokinin-8 exhibit similar actions on calcium signaling, zymogen secretion, and cell fate in murine pancreatic acinar cells, Am. J. Physiol. Liver Physiol. 297 (2009) 1085–1092.
- [45] J.L. Frossard, S. Lenglet, F. Montecucco, S. Steffens, K. Galan, G. Pelli, et al., Role of CCL-2, CCR-2 and CCR-4 in cerulein-induced acute pancreatitis and pancreatitis-associated lung injury, J. Clin. Pathol. 64 (2011) 387–393.
- [46] S. V Popov, G.Y. Popova, R.G. Ovodova, Y.S. Ovodov, Antiinflammatory


- activity of the pectic polysaccharide from *Comarum palustre*, *Fitoterapia*. 76 (2005) 281–287.
- [47] D.W. Barreto, J.P. Parente, Chemical properties and biological activity of a polysaccharide from *Cyrtopodium cardiochilum*, *Carbohydr. Polym.* 64 (2006) 287–291.
- [48] O.A. Olabissi, O. Moussa, O. Moustapha, Z.F. Edgard, Kaf, o Eleonore, et al., Acute toxicity and anti-inflammatory activity of aqueous ethanol extract of root bark of *Ximenia americana* L. (Olacaceae), *African J. Pharm. Pharmacol.* 5 (2011) 806–811.
- [49] V. Morisset, J. Ahluwalia, I. Nagy, L. Urban, Possible mechanisms of cannabinoid-induced antinociception in the spinal cord, *Eur. J. Pharmacol.* 429 (2001) 93–100.
- [50] D. Rani Sagar, J.J. Burston, S.G. Woodhams, V. Chapman, Dynamic changes to the endocannabinoid system in models of chronic pain, *Philos. Trans. R. Soc. Lond. B. Biol. Sci.* 367 (2012) 3300–3311.
- [51] N. Agarwal, P. Pacher, I. Tegeder, F. Amaya, C.E. Constantin, G.J. Brenner, et al., Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors, *Nat. Neurosci.* 10 (2007) 870–879.
- [52] M.D. Van Sickle, M. Duncan, P.J. Kingsley, A. Mouihate, P. Urbani, K. Mackie, et al., Identification and functional characterization of brainstem cannabinoid CB2 receptors, *Science*. 310 (2005) 329–32.
- [53] P. Pacher, R. Mechoulam, Is lipid signaling through cannabinoid 2 receptors part of a protective system?, *Prog. Lipid Res.* 50 (2011) 193–211.
- [54] A.-L. Klauke, I. Racz, B. Pradier, A. Markert, A.M. Zimmer, J. Gertsch, et al., The cannabinoid CB2 receptor-selective phytocannabinoid beta-caryophyllene exerts analgesic effects in mouse models of inflammatory and neuropathic pain, *Eur. Neuropsychopharmacol.* 24 (2014) 608–620.
- [55] J.J. Burston, D.R. Sagar, P. Shao, M. Bai, E. King, L. Brailsford, et al., Cannabinoid CB2 receptors regulate central sensitization and pain responses associated with osteoarthritis of the knee joint, *PLoS One*. 8 (2013) 1–9.
- [56] N. Clayton, F.H. Marshall, C. Bountra, C.T. O’Shaughnessy, CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain, *Pain*. 96 (2002) 253–260.
- [57] J.T. Toguri, C. Lehmann, R.B. Laprairie, A.M. Szczesniak, J. Zhou, E.M.




- Denovan-Wright, et al., Anti-inflammatory effects of cannabinoid CB(2) receptor activation in endotoxin-induced uveitis., *Br. J. Pharmacol.* 171 (2014) 1448–61.
- [58] S.G. Barreto, G.T.P. Saccone, Pancreatic nociception--revisiting the physiology and pathophysiology., *Pancreatology.* 12 (2012) 104–112.
- [59] L.P. Vera-Portocarrero, Y. Lu, K.N. Westlund, Nociception in persistent pancreatitis in rats: effects of morphine and neuropeptide alterations, *Anesthesiology.* 98 (2003) 474–84.
- [60] D. Diallo, B.S. Paulsen, T.H. Liljebäck, T.E. Michaelsen, Polysaccharides from the roots of *Entada africana* Guill. et Perr., Mimosaceae, with complement fixing activity, *J. Ethnopharmacol.* 74 (2001) 159–71.
- [61] K.T. Inngjerdingen, S.C. Debes, M. Inngjerdingen, S. Hokputsa, S.E. Harding, B. Rolstad, et al., Bioactive pectic polysaccharides from *Glinus oppositifolius* (L.) Aug. DC., a Malian medicinal plant, isolation and partial characterization, *J. Ethnopharmacol.* 101 (2005) 204–214.
- [62] J. Li, Q. Li, Y. Peng, R. Zhao, Z. Han, D. Gao, Protective effects of fraction 1a of polysaccharides isolated from *Solanum nigrum* Linne on thymus in tumor-bearing mice, *J. Ethnopharmacol.* 129 (2010) 350–356.
- [63] T.Y. Soro, F. Traore, J. Sakande, Analgesic activity of the aqueous extract from *Ximenia americana*, *C. R. Biol.* 332 (2009) 371–377.
- [64] N.H.T. Le, K.E. Malterud, D. Diallo, B.S. Paulsen, C.S. Nergård, H. Wangensteen, Bioactive polyphenols in *Ximenia americana* and the traditional use among Malian healers, *J. Ethnopharmacol.* 139 (2012) 858–862.




**Fig. 1** NMR of TPL-Xa.  $^1\text{H}$  (A) and  $^{13}\text{C}$  (B).




**Fig. 2 TPL-Xa reduces pancreatic enzymes.** Mice received 10 i.p. injections of caerulein (50 µg/kg) or saline at 1 h intervals. TPL-Xa (10 mg/kg) or saline was administered i.v. 30 min before the first and 30 min after the 10th dose of caerulein. Mice were sacrificed 11 h and 24 h after the caerulein first injection. Blood samples were taken and the plasma levels of amylase (A) and lipase (B) were measured. Mean ± S.E.M. (n = 8). ANOVA and Bonferroni test, \*p<0.05 compared to caerulein; #p<0.05 compared to saline.




**Fig. 3 TPL-Xa inhibits histological damage in acute pancreatitis.** Mice received 10 i.p. injections of caerulein (50  $\mu\text{g}/\text{kg}$ ) or saline at 1 h intervals. TPL-Xa (10 mg/kg) or saline was administered i.v. 30 min before the first and 30 min after the 10th dose of caerulein. Control animals received saline (i.p.) instead of caerulein. Mice were sacrificed at 11 h and 24 h after the first injection of caerulein for histopathological evaluation: (A) Edema; (B) inflammatory infiltration; (C) acinar cell necrosis; (D) total scores. Values are expressed as median (maximum and minimum) (n=6). ANOVA, Kruskal-Wallis followed by Dunn test. \*p<0.05 compared to caerulein; #p<0.05 compared to saline.



**Fig. 4 TPL-Xa inhibits MPO activity in acute pancreatitis.** Mice received 10 i.p. injections of caerulein (50 µg/kg) or saline at 1 h intervals. TPL-Xa (10 mg/kg) or saline was administered i.v. 30 min before the first and 30 min after the 10th dose of caerulein. Control animals received saline (i.p.) instead of caerulein. Mice were sacrificed (A) 11 h and (B) 24 h after the first injection of caerulein for evaluation of MPO activity. Values are expressed as units of MPO (UMPO) per milligram of tissue. Mean ± S.E.M. (n = 8). ANOVA and Bonferroni test. \*p<0.05 compared to caerulein; #p<0.05 compared to saline.



**Fig. 5 TPL-Xa inhibits visceral hypernociception without alteration of locomotor activity.** Mice received 10 i.p. injections of caerulein (50 µg/kg) or saline at 1 h intervals. TPL-Xa (10 mg/kg, i.v.), saline (i.v.) or diazepam (5 mg/kg, i.p.) was administered 30 min before the first and 30 min after the 10th dose of caerulein. (A) Visceral hypernociception was evaluated by the von Frey test at the 11th and 24th h after the first injection of caerulein. (B) Locomotor function was evaluated at the 11th h in the rota-Rod test. Mean ± S.E.M. (n = 8). ANOVA and Bonferroni test. \*p<0.05 compared to caerulein; #p<0.05 compared to saline.



**Fig. 6 Involvement of CB2 cannabinoid receptor in the anti-hypernociceptive effect of TPL-Xa.** Mice received 10 i.p. injections of caerulein (50  $\mu$ g/kg) or saline at 1 h intervals. (A; C) Non-treated animals evaluated at baseline (time zero); (B) Animals pre-treated with saline (i.v.), TPL-Xa (10 mg/kg; i.v.), AM281 (3 mg/kg, s.c.) or TPL-Xa + AM281; (D, E and F) Animals pre-treated with saline (i.v.), TPL-Xa, AM630 (1 mg/kg, s.c.) or TPL-Xa + AM630. (D) Withdrawal threshold (E) showing total histological scores, in the photomicrographs intense neutrophil infiltrate (red arrow) and necrosis (arrowhead). Hypernociception, histological analyses and expression of CB2 was evaluated 11 hours after the first injection of caerulein. Photomicrographs of pancreas tissue (100X magnification). Mean  $\pm$  S.E.M. (n= 8). ANOVA and Bonferroni test. \* $p$ <0.05 compared to caerulein; # $p$ <0.05 compared to saline and (&)  $p$ <0.05 compared to TPL-Xa + caerulein.